Hamilton Wealth LLC Purchases 34,284 Shares of Bristol-Myers Squibb (NYSE:BMY)

Hamilton Wealth LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 106.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,548 shares of the biopharmaceutical company’s stock after buying an additional 34,284 shares during the period. Bristol-Myers Squibb comprises about 1.1% of Hamilton Wealth LLC’s investment portfolio, making the stock its 27th largest holding. Hamilton Wealth LLC’s holdings in Bristol-Myers Squibb were worth $3,609,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. PFG Advisors raised its stake in shares of Bristol-Myers Squibb by 6.1% during the 4th quarter. PFG Advisors now owns 5,649 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 323 shares in the last quarter. Trust Point Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $904,000. Richard W. Paul & Associates LLC grew its stake in shares of Bristol-Myers Squibb by 50.8% in the fourth quarter. Richard W. Paul & Associates LLC now owns 11,791 shares of the biopharmaceutical company’s stock valued at $605,000 after acquiring an additional 3,973 shares in the last quarter. GAM Holding AG boosted its holdings in Bristol-Myers Squibb by 115.3% in the 4th quarter. GAM Holding AG now owns 237,813 shares of the biopharmaceutical company’s stock valued at $12,202,000 after purchasing an additional 127,363 shares during the period. Finally, Visionary Horizons LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $643,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Up 1.2 %

BMY stock traded up $0.60 during trading on Friday, reaching $48.77. 15,601,503 shares of the stock were exchanged, compared to its average volume of 17,378,216. The company has a current ratio of 1.16, a quick ratio of 0.99 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.41. The firm’s 50 day moving average is $42.39 and its 200 day moving average is $46.75. The firm has a market cap of $98.88 billion, a P/E ratio of -15.73, a price-to-earnings-growth ratio of 12.51 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the previous year, the business posted $1.75 EPS. Bristol-Myers Squibb’s quarterly revenue was up 8.7% on a year-over-year basis. As a group, research analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.92%. The ex-dividend date of this dividend was Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Ratings Changes

BMY has been the topic of a number of recent research reports. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Barclays cut shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 price objective for the company. in a research report on Monday, July 29th. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $55.79.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.